{"organizations": [], "uuid": "a90c64aac7405f7971fd1c812ecb3f2cad794541", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/4", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/17/business-wire-arrowhead-pharmaceuticals-announces-proposed-underwritten-offering-of-common-stock.html", "country": "US", "domain_rank": 767, "title": "Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T00:01:00.000+02:00", "replies_count": 0, "uuid": "a90c64aac7405f7971fd1c812ecb3f2cad794541"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/17/business-wire-arrowhead-pharmaceuticals-announces-proposed-underwritten-offering-of-common-stock.html", "ord_in_thread": 0, "title": "Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock", "locations": [], "entities": {"persons": [], "locations": [{"name": "pasadena", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "arrowhead", "sentiment": "none"}], "organizations": [{"name": "arrowhead pharmaceuticals", "sentiment": "negative"}, {"name": "arrowhead pharmaceuticals inc.", "sentiment": "negative"}, {"name": "securities and exchange commission", "sentiment": "none"}, {"name": "sec", "sentiment": "none"}, {"name": "jefferies llc", "sentiment": "none"}, {"name": "barclays capital inc.", "sentiment": "none"}, {"name": "cantor fitzgerald & co.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by Arrowhead.\nJefferies LLC and Barclays Capital Inc. are acting as bookrunnning managers for the offering, and Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering. Arrowhead intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.\nA shelf registration statement on Form S-3 (File No. 333-214315) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the \"SEC\") and is effective. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov . When available, copies of the preliminary prospectus supplement may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com or from Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: Barclaysprospectus@broadridge.com .\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.\nAbout Arrowhead Pharmaceuticals\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheadâ€™s RNAi-based therapeutics leverage this natural pathway of gene silencing.\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\nThis news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding our expectations with respect to our proposed public offering. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss some of the important risk factors that may affect our ability to achieve the anticipated results, as well as our business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.\nSource: Arrowhead Pharmaceuticals, Inc.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180117006411/en/\nArrowhead Pharmaceuticals, Inc.\nVince Anzalone, CFA\n626-304-3400\nir@arrowheadpharma.com\nor\nInvestors and Media:\nLifeSci Advisors, LLC\nBrian Ritchie\n212-915-2578\nbritchie@lifesciadvisors.com\nwww.lifesciadvisors.com\nSource: Arrowhead Pharmaceuticals Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=51744903&newsitemid=20180117006411&lan=en-US&anchor=www.sec.gov&index=1&md5=5b6e050806a875d37b60a9a210572cec", "http://www.businesswire.com/news/home/20180117006411/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.lifesciadvisors.com%2F&esheet=51744903&lan=en-US&anchor=www.lifesciadvisors.com&index=2&md5=6ce776093051d6eba625918d895356b4"], "published": "2018-01-18T00:01:00.000+02:00", "crawled": "2018-01-18T00:25:35.000+02:00", "highlightTitle": ""}